| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Rodman David Malcom serves as a Chief Medical Officer at MLYS. Across recent SEC filings that breaks down to 0 buys and 41 sells. Those positions are worth an estimated $1.4M at current prices.
Historically, Rodman David Malcom's trades have earned a middling insider score of 54/100 across 26 rated trades. Over a 12-month horizon, 27.3% of those trades were profitable, with an average 12-month return of -52.7%.
The biggest single holding is MLYS (~$1.4M) as Chief Medical Officer. The recent filings there lean toward selling, a net 770,567 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | MLYS Mineralys Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 5,026 | $15.00 | $75,398.04 | -3.4% | -36.3% | +215.8% | |
| Nov 6, 2024 | MLYS Mineralys Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 25,482 | $15.03 | $383,065.81 | -15.8% | -31.7% | +147.6% | |
| Jul 16, 2024 | MLYS Mineralys Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 525 | $15.00 | $7,875.58 | -0.5% | -6.8% | -1.8% | |
| May 9, 2024 | MLYS Mineralys Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 100 | $15.00 | $1,500.00 | -0.1% | -21.0% | +2.7% | |
| Aug 11, 2023 | MLYS Mineralys Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 231,716 | $12.92 | $2,994,400.71 | -100% | -42.2% | -14.0% |